SCHEMBL788910

SCHEMBL788910

CC(C)(C)OC(=O)NNC(=O)c1ccc(Br)cc1Cl

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
AAK1 Q2M2I8 1/20 0.46
FLT1 P17948 2/20 0.45
FLT4 P35916 2/20 0.45
KDR P35968 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 1/20 0.44
GAA P10253 3/20 0.43
MEN1 O00255 2/20 0.43
HTT P42858 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789101 0.84 NPC1 (0.51) ALDH1A1AAK1FLT1FLT4KDR
SCHEMBL789057 0.83 USP30 (0.54) ALDH1A1AAK1FLT1FLT4KDR
SCHEMBL29422481 0.83 USP30 (0.54) ALDH1A1AAK1FLT1FLT4KDR
SCHEMBL22843801 0.82 ALDH1A1 (0.56) ALDH1A1FLT1FLT4KDRNPC1
SCHEMBL3137559 0.81 LMNA (0.48) ALDH1A1AAK1SMN1; SMN2NPC1RECQL
SCHEMBL1693101 0.81 AAK1 (0.45) ALDH1A1AAK1SMN1; SMN2NPC1RECQL
SCHEMBL14321549 0.79 AAK1 (0.43) ALDH1A1AAK1FLT1FLT4KDR
SCHEMBL3142703 0.79 ALDH1A1 (0.49) ALDH1A1FLT1FLT4KDRSMN1; SMN2
SCHEMBL17680509 0.77 POLB (0.53) ALDH1A1SMN1; SMN2NPC1RECQLRAB9A
SCHEMBL20866979 0.77 SLC22A12 (0.41) ALDH1A1KDRSMN1; SMN2NPC1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616071-A2 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-24 EP disclosed
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2013-07-04 US disclosed
WO-2012037299-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
US-20100004221-A1 THIAZEPINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-01-07 US disclosed
EP-2119719-A1 THIAZEPINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004221-A1 THIAZEPINE DERIVATIVE HSD11B1, HSD17B1, HSD3B1 ALDH1A1 28/4885AAK1 2798/4885FLT1 3721/4885
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 ALDH1A1 671/4885AAK1 935/4885FLT1 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.